Paradigm Capital Management Inc. NY Takes $24.54 Million Position in Natera, Inc. $NTRA

Posted by Francis Steltz on Aug 25th, 2026

Paradigm Capital Management Inc. NY bought a new stake in Natera, Inc. (NASDAQ:NTRA – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 90,400 shares of the medical research company’s stock, valued at approximately $24,539,000. Natera comprises about 0.7% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 29th biggest holding. Paradigm Capital Management Inc. NY owned approximately 0.06% of Natera as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in NTRA. BlackRock Inc. purchased a new stake in Natera in the 2nd quarter valued at about $2,962,770,000. Coatue Management LLC increased its stake in shares of Natera by 1,446.1% during the 4th quarter. Coatue Management LLC now owns 2,633,334 shares of the medical research company’s stock valued at $603,270,000 after acquiring an additional 2,463,008 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Natera by 94.7% during the 4th quarter. Wellington Management Group LLP now owns 4,976,325 shares of the medical research company’s stock worth $1,140,026,000 after acquiring an additional 2,420,263 shares during the period. Norges Bank purchased a new position in shares of Natera during the 4th quarter worth about $372,398,000. Finally, JPMorgan Chase & Co. boosted its position in shares of Natera by 10.5% in the fourth quarter. JPMorgan Chase & Co. now owns 12,854,334 shares of the medical research company’s stock worth $2,944,800,000 after acquiring an additional 1,225,420 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Natera

In other news, Director Herm Rosenman sold 16,530 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total value of $4,132,500.00. Following the completion of the sale, the director owned 4,250 shares of the company’s stock, valued at $1,062,500. This represents a 79.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Solomon Moshkevich sold 3,410 shares of the stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $265.58, for a total value of $905,627.80. Following the completion of the sale, the insider owned 129,019 shares of the company’s stock, valued at approximately $34,264,866.02. This trade represents a 2.57% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 177,955 shares of company stock valued at $40,704,193 over the last 90 days. Corporate insiders own 5.05% of the company’s stock.

Natera Trading Down 1.3%

NASDAQ:NTRA opened at $327.72 on Tuesday. The firm has a market capitalization of $47.24 billion, a price-to-earnings ratio of -240.97 and a beta of 1.51. The firm’s fifty day simple moving average is $276.45 and its 200 day simple moving average is $230.09. Natera, Inc. has a twelve month low of $157.43 and a twelve month high of $333.56.

Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. During the same period in the prior year, the company earned ($0.74) EPS. The firm’s revenue was up 37.7% on a year-over-year basis. On average, analysts predict that Natera, Inc. will post -1.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NTRA shares. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Barclays reaffirmed an “overweight” rating and set a $340.00 price target on shares of Natera in a research note on Friday, August 7th. UBS Group set a $260.00 price objective on shares of Natera in a research note on Wednesday, June 24th. Stephens upped their price objective on Natera from $305.00 to $350.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Finally, Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $319.38.

Check Out Our Latest Research Report on NTRA

Natera Profile

(Free Report)

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.